Loading clinical trials...
Loading clinical trials...
Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Conditions
Interventions
Semaglutide
Placebo (semaglutide)
Locations
128
United States
Novo Nordisk Investigational Site
Anniston, Alabama, United States
Novo Nordisk Investigational Site
Anaheim, California, United States
Novo Nordisk Investigational Site
Lomita, California, United States
Novo Nordisk Investigational Site
Spring Valley, California, United States
Novo Nordisk Investigational Site
Aurora, Colorado, United States
Novo Nordisk Investigational Site
Waterbury, Connecticut, United States
Start Date
June 4, 2018
Primary Completion Date
March 30, 2020
Completion Date
March 5, 2021
Last Updated
November 19, 2021
NCT06857942
NCT07499050
NCT07160400
NCT07150962
NCT06499857
NCT04824248
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions